Nanomedicines for the treatment of inflammatory bowel diseases

European Journal of Nanomedicine

Volumn 5, Issue 1, 2013, Pages 23-38

  Ali, Hussain ^a   Collnot, Eva Maria ^a   Windbergs, Maike ^a   Lehr, Claus Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Animal model; Inflammatory bowel disease; Nanoparticles; Targeted delivery

Indexed keywords

ANIMAL MODEL; ANTI-INFLAMMATORY DRUGS; DELIVERY SYSTEMS; DOSING FREQUENCY; GASTROINTESTINAL TRACT; INFLAMMATORY BOWEL DISEASE; TARGETED DELIVERY; ULCERATIVE COLITIS;

DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

DIAGNOSIS;

ADALIMUMAB; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CATALASE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; EUDRAGIT; INFLIXIMAB; INTERLEUKIN 10; LOW MOLECULAR WEIGHT HEPARIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MICROSPHERE; NANOCARRIER; NANOSPHERE; OLSALAZINE; PREDNISOLONE; ROLIPRAM; SALAZOSULFAPYRIDINE; SMALL INTERFERING RNA; SULFONAMIDE; SUPEROXIDE DISMUTASE; TACROLIMUS;

ARTHRITIS; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; NANOMEDICINE; PANCOLITIS; REMISSION; REVIEW;

EID: 84882314627     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2013-0004     Document Type: Review

References (132)

1. Head KA, Jurenka JS. Inflammatory bowel disease Part 1: Ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003;8: 247-83.
2. Gramlich T, Petras RE. Pathology of inflammatory bowel disease. Semin Pediatr Surg 2007;16:154-63.
3. Fiorino G, Fries W, De La Rue SA, Malesci AC, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem 2010;17:1851-7.
4. Meissner Y, Lamprecht A. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J Pharm Sci 2008;97:2878-91.
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
6. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
7. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001;276:4812-8.
8. Koutroubakis I, Manousos ON, Meuwissen SG, Pena AS. Environmental risk factors in inflammatory bowel disease. Hepato-Gastroenterol 1996;43:381-93.
9. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down ? World J Gastroenterol 2006;12:6102-8.
10. Kurata JH, Kantor-Fish S, Frankl H, Godby P, Vadheim CM. Crohn's disease among ethnic groups in a large health maintenance organization. Gastroenterology 1992;102: 1940-8.
11. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
12. Baumgart DC, Carding SR. Inflammatory bowel disease: Cause and immunobiology. Lancet 2007;369:1627-40.
13. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
14. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000;119:1740-4.
15. Soderholm JD, Olaison G, Peterson KH, Franzen LE, Lindmark T, Wiren M, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 2002;50:307-13.
16. Pallone F, Monteleone G. Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut 1998;43:735-6.
17. Shanahan F. Crohn's disease. Lancet 2002;359:62-9.
18. Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999;116: 557-65.
19. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
20. Wagtmans MJ, Verspaget HW, Lamers CB, Hogezand RA. Gender-related differences in the clinical course of Crohn's disease. Am J Gastroenterol 2001;96:1541-6.
21. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53:V1-16.
22. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99: 1371-85.
23. Sandborn WJ, Hanauer SB. Systematic review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42.
24. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005;57:267-79.
25. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
26. Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, et al. National Cooperative Crohn's Disease Study: Study design and conduct of the study. Gastroenterology 1979;77:829-42.
27. Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Revista de gastroenterologia de Mexico 2006;71:351-401.
28. Angeli A, Masera RG, Sartori ML, Fortunati N, Racca S, Dovio A, et al. Modulation by cytokines of glucocorticoid action. Ann NY Acad Sci 1999;876:210-20.
29. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255-60.
30. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: Analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24:319-30.
31. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982;122:86-95.
32. Krishnamachari Y, Madan P, Lin S. Development of pH-and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 2007;338:238-47.
33. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53.
34. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
35. Baugh JA, Bucala R. Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr Opin Drug Discov Develop 2001;4:635-50.
36. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817-28.
37. Jackson JM. TNF-alpha inhibitors. Dermatol Ther 2007;20: 251-64.
38. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
39. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review. Digest Dis (Basel, Switzerland) 1994;12: 290-304.
40. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
41. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
42. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
43. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
44. Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, et al. A multicenter experience with infliximab for ulcerative colitis: Outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;105:2617-25.
45. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
46. van Deventer SJ, Camoglio L. Monoclonal antibody therapy of inflammatory bowel disease. Aliment Pharmacol Ther 1996;10(Suppl 2):107-11; discussion 12.
47. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
48. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
49. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
50. Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: Focus on certolizumab pegol (CDP870). Int J Nanomedicine 2007;2:39-47.
51. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
52. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32.
53. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: Current management. Gut 2006;55(Suppl 1):i16-35.
54. Campieri M. New steroids and new salicylates in inflammatory bowel disease: A critical appraisal. Gut 2002;50(Suppl 3): III43-6.
55. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5.
56. Sinha VR, Kumria R. Colonic drug delivery: Prodrug approach. Pharm Res 2001;18:557-64.
57. Carrette O, Favier C, Mizon C, Neut C, Cortot A, Colombel JF, et al. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 1995;40:2641-6.
58. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48:571-7.
59. Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993;38:1989-93.
60. Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: Colonic luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol 1997;92:114-8.
61. Watts PJ, Barrow L, Steed KP, Wilson CG, Spiller RC, Melia CD, et al. The transit rate of different-sized model dosage forms through the human colon and the effects of a Lactulose-Induced Catharsis. Int J Pharm 1992;87:215-21.
62. Urayama S, Chang EB. Mechanisms and treatment of diarrhea in inflammatory bowel diseases. Inflamm Bowel Dis 1997;3: 114-31.
63. European Science Foundation, European medical Research Councils (EMRC), Forward Look report. Consensus Conference, Le Bischenberg, France, 2005.
64. European Union Scientific Committee on Emerging and Newly Identified Health Risk (SCENIHR). Scientific Basis for the Definition of the Term " nanomaterial ", Brussels, 2010. ISBN 978-92-79-12757-1; doi:10.2772/39703; ND-AS-09-004-EN-N.
65. Maitra A. Opinion: Does nanomedicine really belong to the field of nanotechnology? Available at: Http://www.nanomagazine. co.uk, Accessed on 6 August, 2010.
66. Duncan R, Gaspar R. Nanomedicine(s) under the Microscope. Mol Pharmaceut 2011;8:2101-41.
67. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliver Rev 2012;64:61-71.
68. Collnot EM, Ali H, Lehr CM. Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release 2012;161:235-46.
69. Ulbrich W, Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J R Soc Interface 2010;7(Suppl 1):S55-66.
70. Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharmaceut 2012;9:2961-73.
71. Xiao B, Merlin D. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2012;9:1393-407.
72. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: The state of the art. Critical reviews in therapeutic drug carrier systems 2004;21:387-422.
73. Shenoy DB, Amiji MM. Poly(ethylene oxide)-modified poly(epsilon- caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 2005;293:261-70.
74. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001;46:75-87.
75. Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: Promising vehicle for bioactive drugs. Biol Pharm Bull 2006;29:1790-8.
76. Moulari B, Pertuit D, Pellequer Y, Lamprecht A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials 2008;29:4554-60.
77. Mladenovska K, Raicki RS, Janevik EI, Ristoski T, Pavlova MJ, Kavrakovski Z, et al. Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. Int J Pharm 2007;342:124-36.
78. Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaili L, et al. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release 2007;123:211-8.
79. Rodriguez M, Antunez JA, Taboada C, Seijo B, Torres D. Colon-specific delivery of budesonide from microencapsulated cellulosic cores: Evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol 2001;53:1207-15.
80. Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally-induced colitis rat model. Eur J Pharm Biopharm 2009;72:1-8.
81. Crcarevska MS, Dodov MG, Petrusevska G, Gjorgoski I, Goracinova K. Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis. J Drug Target 2009;17:788-802.
82. Oosegi T, Onishi H, Machida Y. Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int J Pharm 2008;348:80-8.
83. Onishi H, Oosegi T, Machida Y. Efficacy and toxicity of Eudragitcoated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis. Int J Pharm 2008;358:296-302.
84. Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery. Int J Pharm 2006;316:138-43.
85. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release 2005;104:337-46.
86. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001;299:775-81.
87. Fukata N, Uchida K, Kusuda T, Koyabu M, Miyoshi H, Fukui T, et al. The effective therapy of cyclosporine A with drug delivery system in experimental colitis. J Drug Target 2011;19:458-67.
88. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008;15:1200-9.
89. Kriegel C, Amiji M. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release 2011;150:77-86.
90. Wilson DS, Dalmasso G, Wang LX, Sitaraman SV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nature Mater 2010;9: 923-8.
91. Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010;138:843-53 e1-2.
92. Jubeh TT, Nadler-Milbauer M, Barenholz Y, Rubinstein A. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target 2006;14:155-63.
93. Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004;25:1771-7.
94. Lamprecht A. IBD: Selective nanoparticle adhesion can enhance colitis therapy. Nat Rev Gastroenterol Hepatol 2010;7:311-2.
95. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 2001;18:788-93.
96. Dvorak AM, Dickersin GR. Crohn's disease: Transmission electron microscopic studies. I. Barrier function. Possible changes related to alterations of cell coat, mucous coat, epithelial cells, and Paneth cells. Hum Pathol 1980; 11(Suppl 5):561-71.
97. Silverstein SC, Steinman RM, Cohn ZA. Endocytosis. Annu Rev Biochem 1977;46:669-722.
98. van Oss CJ. Phagocytosis as a surface phenomenon. Annu Rev Microbiol 1978;32:19-39.
99. D'Souza MJ, DeSouza P. Site specific microencapsulated drug targeting strategies-Liver and gastro-intestinal tract targeting. Adv Drug Deliver Rev 1995;17:247-54.
100. Mullerad J, Cohen S, Benharroch D, Apte RN. Local delivery of IL-1 alpha polymeric microspheres for the immunotherapy of an experimental fibrosarcoma. Cancer Invest 2003;21:720-8.
101. Kanke M, Geissler RG, Powell D, Kaplan A, DeLuca PP. Interaction of microspheres with blood constituents. III. Macrophage phagocytosis of various types of polymeric drug carriers. J Parenter Sci Technol 1988;42:157-65.
102. Okawa T, Ichimal H, Ishida T, Kawata M, Kaguba S, Mamba K, et al. Implication of activation of intraperitoneal macrophages with bio-degradable microspheres. Cell Biol Int Rep 1989;13:547-53.
103. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002;79:29-40.
104. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Lehr CM, et al. Design of rolipram-loaded nanoparticles: Comparison of two preparation methods. J Control Release 2001;71:297-306.
105. Mahajan N, Sakarkar D, Manmode A, Pathak V, Ingole R, Dewade D. Biodegradable nanoparticles for targeted delivery in treatment of ulcerative colitis. Adv Sci Lett 2011;4:349-56.
106. Lamprecht A, Yamamoto H, Ubrich N, Takeuchi H, Maincent P, Kawashima Y. FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression. Pharm Res 2005;22:193-9.
107. Jubeh TT, Barenholz Y, Rubinstein A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharmaceut Res 2004;21:447-53.
108. Kesisoglou F, Zhou SY, Niemiec S, Lee JW, Zimmermann EM, Fleisher D. Liposomal formulations of inflammatory bowel disease drugs: Local versus systemic drug delivery in a rat model. Pharmaceut Res 2005;22:1320-30.
109. Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, et al. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: An open trial. Dig Dis Sci 2001;46:2239-44.
110. Torkvist L, Thorlacius H, Sjoqvist U, Bohman L, Lapidus A, Flood L, et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999;13:1323-8.
111. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1403-9.
112. Pellequer Y, Meissner Y, Ubrich N, Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 2007;321:726-33.
113. Laroui H, Theiss AL, Yan Y, Dalmasso G, Nguyen HT, Sitaraman SV, et al. Functional TNFalpha gene silencing mediated by polyethyleneimine/TNFalpha siRNA nanocomplexes in inflamed colon. Biomaterials 2011;32:1218-28.
114. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458:1180-4.
115. Matthew Barnett AF. Animal models of colitis: Lasson learned and their relevance to the clinic. [Book Chapter]. 2011:161-78.
116. MacPherson BR, Pfeiffer CJ. Experimental production of diffuse colitis in rats. Digestion 1978;17:135-50.
117. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
118. Ishioka T, Kuwabara N, Oohashi Y, Wakabayashi K. Induction of colorectal tumors in rats by sulfated polysaccharides. Crit Rev Toxicol 1987;17:215-44.
119. Moyana TN, Lalonde JM. Carrageenan-induced intestinal injury in the rat-A model for inflammatory bowel disease. Ann Clin Lab Sci 1990;20:420-6.
120. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
121. Rachmilewitz D, Simon PL, Schwartz LW, Griswold DE, Fondacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989;97: 326-37.
122. Kocak E, Koklu S, Akbal E, Tas A, Karaca G, Astarci MH, et al. NaOH-induced Crohn's colitis in rats: A novel experimental model. Dig Dis Sci 2011;56:2833-7.
123. Alex P, Zachos NC, Conklin LS, Kwon JH, Harris ML, Bayless TM, et al. Distinct cytokine patterns as effective indicators of disease activity and severity in IBD. Gastroenterology 2008;134:A204-A.
124. Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, et al. T cell transfer model of chronic colitis: Concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol 2009;296:G135-46.
125. Hoffmann JC, Pawlowski NN, Kuhl AA, Hohne W, Zeitz M. Animal models of inflammatory bowel disease: An overview. Pathobiology 2002;70:121-30.
126. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-83.
127. Leonard F, Ali H, Collnot EM, Crielaard BJ, Lammers T, Storm G, et al. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model. ALTEX 2012;29:275-85.
128. Leonard F, Collnot EM, Lehr CM. A Three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro. Mol Pharmaceut 2010;7:2103-19.
129. Berg DK, Smith CS, Pearton DJ, Wells DN, Broadhurst R, Donnison M, et al. Trophectoderm lineage determination in cattle. Dev Cell 2011;20:244-55.
130. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH fluid and lymphoid tissue, and implications for in vivo experiments. J Pharm Pharmacol 2008;60:63-70.
131. Schmidt C, Lautenschlaeger C, Collnot EM, Schumann M, Bojarski C, Schulzke JD, et al. Nano-and microscaled particles for drug targeting to inflamed intestinal mucosa-A first in vivo study in human patients. J Control Release 2012;165: 139-45.
132. Harel E, Rubinstein A, Nissan A, Khazanov E, Nadler Milbauer M, Barenholz Y, et al. Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa. PLoS One 2011;6:e24202.